Board of Directors
Mr. Yanling Cao is a founding member and Managing Director of Boyu Capital and has been in charge of investments and portfolio management in the healthcare sector since 2011. He currently serves on the boards of a number of leading pharmaceutical, diagnostic and healthcare service companies in China. Prior to Boyu, Mr. Cao worked as an investment professional at General Atlantic and Goldman Sachs on a wide range of strategic and financial transactions. Mr. Cao received Bachelor of Arts in Economics and Mathematics, summa cum laude, from Middlebury College.
Mr. Edward Hu is Co-Chief Executive Officer at WuXi AppTec. Mr. Hu manages WuXi AppTec’s finance, investments, mergers and acquisitions, joint ventures, and new business and capability building. Mr. Hu previously served as WuXi’s chief operating officer and chief financial officer for five years until April 2014. Prior to joining WuXi in August 2007, he was a senior vice president and chief operating officer at Tanox, a biopharmaceutical company acquired by Genentech. He also held positions at Merck & Co., Inc. as a senior financial analyst and later in business and financial planning at Biogen, Inc. Mr. Hu earned his B.S. in Physics from Zhejiang University, and his M.S. in Chemistry and MBA from Carnegie Mellon University.
Mr. Chris Nolet was the West Region Life Sciences Industry Leader & Partner at Ernst & Young from 2002 until 2019 and has more than 38 years of experience in the profession. In addition to serving a wide array of clients, his responsibilities included leading West Region EY Life Sciences Industry Group and serving as a member of the Global EY Life Sciences Executive Leadership Group, which established policies and operating strategies for EY Life Sciences practice worldwide. He currently serves on both the Executive Committee and Audit Committee (Chair) of the California Life Sciences Industry Association, the board of directors of Revance Therapeutics, Inc., a biotechnology company, and is a former member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization. Prior to joining EY, Mr. Nolet was a partner at PricewaterhouseCoopers where he led the Life Sciences practice in the western U.S. Mr. Nolet has a B.S. in Accounting from San Diego State University and is a Certified Public Accountant in California.
Dr. Tyrell Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures where he specialized in biotechnology investing, and at Merck & Co., Inc., where he led technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development. Dr. Rivers earned his BSc in Chemical Engineering from the Massachusetts Institute of Technology, a Ph.D. in Chemical Engineering from University of Texas at Austin, and his MBA from the New York University Stern School of Business. Dr. Rivers also serves on the Board of Directors for G1 Therapeutics (GTHX), Corvidia Therapeutics and Armaron Bio Ltd and as a Board observer for several private companies.
Pascal is Executive Director and Chief Executive Officer of AstraZeneca. He brings a passion for science and medicine as well as significant experience in established and emerging markets, strength of strategic thinking, a successful track record of managing change and executing strategy, and the ability to lead a diverse organization. He served as Chief Operating Officer of Roche’s pharmaceuticals division from 2010 to September 2012 and, prior to that, Chief Executive Officer of Genentech, a biologics business, where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in numerous major companies around the world. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.
Mr. Sean Tong is co-founder and Managing Partner of Boyu Capital and currently serves on the board of a number of publicly listed and privately held companies. Prior to Boyu, he was a Managing Director and Head of Greater China at General Atlantic LLC and Providence Equity Partners. He graduated magna cum laude from Harvard University.
Andreas Wicki is Chief Executive Officer of HBM Healthcare Investments AG, Europe’s largest private equity focused investment company dedicated to life sciences. Prior to this role, from 1990-1998, he was co-owner and Chief Executive Officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences CRO companies which he then sold to MDS Inc., a major life sciences services and clinical research organization. After the acquisition, from 1998-2001, he was Senior Vice President of the European Analytical Operations at MDS Inc., which allowed him to become more active in analyzing, selecting, and financing biotech and medtech companies. Dr. Wicki holds an MSc and Ph.D. in chemistry and biochemistry from the University of Bern, Switzerland. He currently serves on the Board of Directors of Buchler GmbH, HBM BioCapital Ltd., HBM Healthcare Investments (Cayman) Ltd., Vitaeris Inc., Harmony Biosciences LLC, and Pacira BioSciences, Inc.
Bing has more than 20 years of experience in the biopharmaceutical industry, with a proven track record of successfully leading the discovery and development of multiple biotherapeutics. Most recently, Bing was Senior Vice President, Head of Respiratory, Inflammation, Autoimmune iMED, MedImmune, AstraZeneca. During his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology indications. Previously, Bing also served as Senior Vice President, Head of Immuno-Oncology Franchise, AstraZeneca, as well as CEO for WuXi-MedImmune Joint Venture. Bing joined MedImmune in 2010 from Genentech, where he was the Head of PTL for Immunology, Infectious Diseases, Neuroscience, and Metabolic Disease, and was Vice President and Head of Research for Tanox, before it was acquired by Genentech in 2007. Bing has also held several positions of increasing responsibility at Aventis and Amgen and currently serves on the Board of Directors for NexImmune. Bing received his Ph.D. in Microbiology and Immunology from the University of Iowa, followed by postdoctoral work at Immunex.